Local control by salvage stereotactic body radiotherapy for recurrent/residual hepatocellular carcinoma after other local therapies

References

• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
   PubMed Web of Science ®Google Scholar
• Marrero JA, Kulik LM, Sirlin CB, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases. Hepatology. 2018;68(2):723–750.
   PubMed Web of Science ®Google Scholar
• Galle PR, Forner A, Llovet JM, et al. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182–236.
   PubMed Web of Science ®Google Scholar
• Bruix J, Sherman M. Practice Guidelines Committee AAftSoLD. Management of hepatocellular carcinoma. Hepatology. 2005;42(5):1208–1236.
   PubMed Web of Science ®Google Scholar
• Liu JH, Chen PW, Asch SM, et al. Surgery for hepatocellular carcinoma: does it improve survival? Ann Surg Oncol. 2004;11(3):298–303.
   PubMed Web of Science ®Google Scholar
• Rim CH, Kim HJ, Seong J. Clinical feasibility and efficacy of stereotactic body radiotherapy for hepatocellular carcinoma: a systematic review and meta-analysis of observational studies. Radiother Oncol. 2019;131:135–144.
   PubMed Web of Science ®Google Scholar
• Ohri N, Tome WA, Mendez Romero A, et al. Local control after stereotactic body radiation therapy for liver tumors. Int J Radiat Oncol Biol Phys. 2018.
   Google Scholar
• Ohri N, Dawson LA, Krishnan S, et al. Radiotherapy for hepatocellular carcinoma: new indications and directions for future study. J Natl Cancer Inst. 2016;108(9).
   PubMedGoogle Scholar
• Benson AB, D'Angelica MI, Abbott DE, et al. Hepatobiliary Cancers, Version 1.2017: featured updates to the NCCN guidelines. J Natl Compr Cancer Netw. 2017;15(5):563–573.
   PubMed Web of Science ®Google Scholar
• Buckstein M, Kim E, Fischman A, et al. Stereotactic body radiation therapy following transarterial chemoembolization for unresectable hepatocellular carcinoma. J Gastrointest Oncol. 2018;9(4):734–740.
   PubMed Web of Science ®Google Scholar
• Honda Y, Kimura T, Aikata H, et al. Stereotactic body radiation therapy combined with transcatheter arterial chemoembolization for small hepatocellular carcinoma. J Gastroenterol Hepatol. 2013;28(3):530–536.
   PubMed Web of Science ®Google Scholar
• Kang JK, Kim MS, Cho CK, et al. Stereotactic body radiation therapy for inoperable hepatocellular carcinoma as a local salvage treatment after incomplete transarterial chemoembolization. Cancer. 2012;118(21):5424–5431.
   PubMed Web of Science ®Google Scholar
• Francis PA, Pagani O, Fleming GF, et al. Tailoring adjuvant endocrine therapy for premenopausal breast cancer. N Engl J Med. 2018;379(2):122–137.
   PubMed Web of Science ®Google Scholar
• Mori S, Kanematsu N, Mizuno H, et al. Physical evaluation of CT scan methods for radiation therapy planning: comparison of fast, slow and gating scan using the 256-detector row CT scanner. Phys Med Biol. 2006;51(3):587–600.
   PubMed Web of Science ®Google Scholar
• Takeda A, Kunieda E, Shigematsu N, et al. Small lung tumors: long-scan-time CT for planning of hypofractionated stereotactic radiation therapy – initial findings. Radiology. 2005;237(1):295–300.
   PubMed Web of Science ®Google Scholar
• Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30(1):52–60.
   PubMed Web of Science ®Google Scholar
• Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 2013;48(3):452–458.
   PubMed Web of Science ®Google Scholar
• Pan CC, Kavanagh BD, Dawson LA, et al. Radiation-associated liver injury. Int J Radiat Oncol Biol Phys. 2010;76(3):S94–S100.
   PubMed Web of Science ®Google Scholar
• Imai K, Beppu T, Chikamoto A, et al. Salvage treatment for local recurrence of hepatocellular carcinoma after local ablation therapy. Hepatol Res. 2014;44(14):E335–E345.
   PubMed Web of Science ®Google Scholar
• Mima K, Hayashi H, Imai K, et al. High CD44s expression is associated with the EMT expression profile and intrahepatic dissemination of hepatocellular carcinoma after local ablation therapy. J Hepato-Biliary-Pancreatic Sci. 2013;20(4):429–434.
   PubMed Web of Science ®Google Scholar
• Lai JP, Conley A, Knudsen BS, et al. Hypoxia after transarterial chemoembolization may trigger a progenitor cell phenotype in hepatocellular carcinoma. Histopathology. 2015;67(4):442–450.
   PubMed Web of Science ®Google Scholar
• Nahm JH, Rhee H, Kim H, et al. Increased expression of stemness markers and altered tumor stroma in hepatocellular carcinoma under TACE-induced hypoxia: a biopsy and resection matched study. Oncotarget. 2017;8(59):99359–99371.
   PubMedGoogle Scholar
• Mima K, Okabe H, Ishimoto T, et al. CD44s regulates the TGF-beta-mediated mesenchymal phenotype and is associated with poor prognosis in patients with hepatocellular carcinoma. Cancer Res. 2012;72(13):3414–3423.
   PubMed Web of Science ®Google Scholar
• Chen L, Chan TH, Yuan YF, et al. CHD1L promotes hepatocellular carcinoma progression and metastasis in mice and is associated with these processes in human patients. J Clin Invest. 2010;120(4):1178–1191.
   PubMed Web of Science ®Google Scholar
• Lee TK, Poon RT, Yuen AP, et al. Twist overexpression correlates with hepatocellular carcinoma metastasis through induction of epithelial–mesenchymal transition. Clin Cancer Res. 2006;12(18):5369–5376.
   PubMed Web of Science ®Google Scholar
• Polyak K, Weinberg RA. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer. 2009;9(4):265–273.
   PubMed Web of Science ®Google Scholar
• Thiery JP, Acloque H, Huang RY, et al. Epithelial–mesenchymal transitions in development and disease. Cell. 2009;139(5):871–890.
   PubMed Web of Science ®Google Scholar
• Yang MH, Chen CL, Chau GY, et al. Comprehensive analysis of the independent effect of twist and snail in promoting metastasis of hepatocellular carcinoma. Hepatology. 2009;50(5):1464–1474.
   PubMed Web of Science ®Google Scholar
• Lam VW, Ng KK, Chok KS, et al. Risk factors and prognostic factors of local recurrence after radiofrequency ablation of hepatocellular carcinoma. J Am Coll Surg. 2008;207(1):20–29.
   PubMed Web of Science ®Google Scholar
• Pan YX, Xi M, Fu YZ, et al. Stereotactic body radiotherapy as a salvage therapy after incomplete radiofrequency ablation for hepatocellular carcinoma: a retrospective propensity score matching study. Cancers (Basel). 2019;11(8):1116.
   PubMed Web of Science ®Google Scholar
• Takeda A, Sanuki N, Tsurugai Y, et al. Stereotactic body radiotherapy for patients with oligometastases from colorectal cancer: risk-adapted dose prescription with a maximum dose of 83–100 Gy in five fractions. J Radiat Res. 2016;57(4):400–405.
   PubMed Web of Science ®Google Scholar
• Andratschke N, Alheid H, Allgauer M, et al. The SBRT database initiative of the German Society for Radiation Oncology (DEGRO): patterns of care and outcome analysis of stereotactic body radiotherapy (SBRT) for liver oligometastases in 474 patients with 623 metastases. BMC Cancer. 2018;18(1):283.
   PubMed Web of Science ®Google Scholar
• Joo JH, Park JH, Kim JC, et al. Local control outcomes using stereotactic body radiation therapy for liver metastases from colorectal cancer. Int J Radiat Oncol Biol Phys. 2017;99(4):876–883.
   PubMed Web of Science ®Google Scholar
• Mahadevan A, Blanck O, Lanciano R, et al. Stereotactic body radiotherapy (SBRT) for liver metastasis – clinical outcomes from the international multi-institutional RSSearch(R) Patient Registry. Radiat Oncol. 2018;13(1):26.
   PubMedGoogle Scholar
• Petrelli F, Comito T, Barni S, et al. Stereotactic body radiotherapy for colorectal cancer liver metastases: a systematic review. Radiother Oncol. 2018;129(3):427–434.
   PubMed Web of Science ®Google Scholar
• Yamashita H, Onishi H, Matsumoto Y, et al. Local effect of stereotactic body radiotherapy for primary and metastatic liver tumors in 130 Japanese patients. Radiat Oncol. 2014;9(1):112.
   PubMedGoogle Scholar
• Uemoto K, Doi H, Shiomi H, et al. Clinical assessment of micro-residual tumors during stereotactic body radiation therapy for hepatocellular carcinoma. Anticancer Res. 2018;38(2):945–954.
   PubMed Web of Science ®Google Scholar
• Kuo HT, Que J, Lin LC, et al. Impact of tumor size on outcome after stereotactic body radiation therapy for inoperable hepatocellular carcinoma. Medicine (Baltimore). 2017;96(50):e9249.
   PubMed Web of Science ®Google Scholar
• Wahl DR, Stenmark MH, Tao Y, et al. Outcomes after stereotactic body radiotherapy or radiofrequency ablation for hepatocellular carcinoma. J Clin Oncol. 2016;34(5):452–459.
   PubMed Web of Science ®Google Scholar
• Scorsetti M, Comito T, Cozzi L, et al. The challenge of inoperable hepatocellular carcinoma (HCC): results of a single-institutional experience on stereotactic body radiation therapy (SBRT). J Cancer Res Clin Oncol. 2015;141(7):1301–1309.
   PubMed Web of Science ®Google Scholar
• Bibault JE, Dewas S, Vautravers-Dewas C, et al. Stereotactic body radiation therapy for hepatocellular carcinoma: prognostic factors of local control, overall survival, and toxicity. PLoS One. 2013;8(10):e77472.
   PubMed Web of Science ®Google Scholar
• Jang WI, Kim MS, Bae SH, et al. High-dose stereotactic body radiotherapy correlates increased local control and overall survival in patients with inoperable hepatocellular carcinoma. Radiat Oncol. 2013;8(1):250.
   PubMedGoogle Scholar
• Jackson WC, Suresh K, Maurino C, et al. A mid-treatment break and reassessment maintains tumor control and reduces toxicity in patients with hepatocellular carcinoma treated with stereotactic body radiation therapy. Radiother Oncol. 2019;141:101–107.
   PubMed Web of Science ®Google Scholar
• Schaub SK, Hartvigson PE, Lock MI, et al. Stereotactic body radiation therapy for hepatocellular carcinoma: current trends and controversies. Technol Cancer Res Treat. 2018;17.
   PubMed Web of Science ®Google Scholar
• Sanuki N, Takeda A, Oku Y, et al. Stereotactic body radiotherapy for small hepatocellular carcinoma: a retrospective outcome analysis in 185 patients. Acta Oncol. 2014;53(3):399–404.
   PubMed Web of Science ®Google Scholar